1037.3000 -10.55 (-1.01%)
NSE Sep 19, 2025 15:31 PM
Volume: 1.1M
 

1037.30
-1.01%
Angel Broking
For 2QFY2017, Cadila Healthcare posted lower than expected results with sales at Rs2,336cr (vs. Rs2,737cr expected vs. Rs2,267cr in 2QFY2016), a yoy growth of 3.1%. On the operating front, the EBITDA margin came in at 21.4% (vs. 21.7% expected vs. 20.3% in 2QFY2016). The dip in the OPM was saved in spite of an underperformance on the sale..
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended